{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:59:55Z","timestamp":1792670395652,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12325-025-03458-3","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:39:07Z","timestamp":1768977547000},"page":"1213-1238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dupilumab Treatment Up to 5\u00a0Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct01949311","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02260986","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-6587","authenticated-orcid":false,"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-9925","authenticated-orcid":false,"given":"Mette","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-8273","authenticated-orcid":false,"given":"Takeshi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2826-7896","authenticated-orcid":false,"given":"Ryszard","family":"Galus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-6993","authenticated-orcid":false,"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Avetisova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8347-7426","authenticated-orcid":false,"given":"Mike","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"3","key":"3458_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"AAAAI\/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274\u2013312. https:\/\/doi.org\/10.1016\/j.anai.2023.11.009.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"3458_CR2","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","volume":"5","author":"M Boguniewicz","year":"2017","unstructured":"Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519\u201331. https:\/\/doi.org\/10.1016\/j.jaip.2017.08.005.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3458_CR3","unstructured":"Dupixent 300\u00a0mg solution for injection in pre-filled pen. Summary of Product Characteristics. EMC. 2024. https:\/\/www.medicines.org.uk\/emc\/product\/11321\/smpc. Accessed 22 Aug 2025."},{"key":"3458_CR4","unstructured":"Dupixent (dupilumab). Highlights of Prescribing Information. US Food and Drug Administration. Revised September 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761055s064lbl.pdf. Accessed 22 Aug 2025."},{"issue":"14","key":"3458_CR5","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111(14):5147\u201352. https:\/\/doi.org\/10.1073\/pnas.1323896111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"3458_CR6","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111(14):5153\u20138. https:\/\/doi.org\/10.1073\/pnas.1324022111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3458_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type\u00a02 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350. https:\/\/doi.org\/10.1038\/nrd4624.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3458_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337. https:\/\/doi.org\/10.1080\/1744666X.2017.1298443.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"3458_CR9","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type\u00a02 inflammation. Allergy. 2020;75(5):1188\u2013204. https:\/\/doi.org\/10.1111\/all.14151.","journal-title":"Allergy"},{"issue":"24","key":"3458_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase\u00a03 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"5","key":"3458_CR11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase\u00a0III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178(5):1083\u2013101. https:\/\/doi.org\/10.1111\/bjd.16156.","journal-title":"Br J Dermatol"},{"issue":"10086","key":"3458_CR12","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase\u00a03 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"1","key":"3458_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase\u00a03 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"3458_CR14","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11\u00a0years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase\u00a03 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054.","journal-title":"J Am Acad Dermatol"},{"issue":"10356","key":"3458_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6\u00a0months to younger than 6\u00a0years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2022;400(10356):908\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2.","journal-title":"Lancet"},{"issue":"3","key":"3458_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s12325-023-02753-1","volume":"41","author":"AS Paller","year":"2024","unstructured":"Paller AS, Pinter A, Wine Lee L, et al. Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6\u00a0months to 5\u00a0years with severe atopic dermatitis. Adv Ther. 2024;41(3):1046\u201361. https:\/\/doi.org\/10.1007\/s12325-023-02753-1.","journal-title":"Adv Ther"},{"issue":"8","key":"3458_CR17","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","volume":"160","author":"LA Beck","year":"2024","unstructured":"Beck LA, Bissonnette R, Deleuran M, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol. 2024;160(8):805\u201312. https:\/\/doi.org\/10.1001\/jamadermatol.2024.1536.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"3458_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40257-024-00859-y","volume":"25","author":"AS Paller","year":"2024","unstructured":"Paller AS, Siegfried EC, Simpson EL, et al. Dupilumab safety and efficacy up to 1\u00a0year in children aged 6\u00a0months to 5\u00a0years with atopic dermatitis: results from a phase\u00a03 open-label extension study. Am J Clin Dermatol. 2024;25(4):655\u201368. https:\/\/doi.org\/10.1007\/s40257-024-00859-y.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"3458_CR19","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1007\/s13555-023-01016-9","volume":"13","author":"MJ Cork","year":"2023","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, et al. Dupilumab safety and efficacy in a phase\u00a0III open-label extension trial in children 6\u201311\u00a0years of age with severe atopic dermatitis. Dermatol Ther (Heidelb). 2023;13(11):2697\u2013719. https:\/\/doi.org\/10.1007\/s13555-023-01016-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"3458_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","volume":"23","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Guttman-Yassky E, Paller AS, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week\u00a052 from a phase\u00a0III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365\u201383. https:\/\/doi.org\/10.1007\/s40257-022-00683-2.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"3458_CR21","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1080\/09546634.2020.1871463","volume":"33","author":"LA Beck","year":"2022","unstructured":"Beck LA, Tha\u00e7i D, Deleuran M, et al. Laboratory safety of dupilumab for up to 3\u00a0years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. J Dermatolog Treat. 2022;33(3):1608\u201316. https:\/\/doi.org\/10.1080\/09546634.2020.1871463.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"3458_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","volume":"21","author":"LA Beck","year":"2020","unstructured":"Beck LA, Tha\u00e7i D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3\u00a0years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567\u201377. https:\/\/doi.org\/10.1007\/s40257-020-00527-x.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"3458_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40272-021-00459-x","volume":"23","author":"AS Paller","year":"2021","unstructured":"Paller AS, Wollenberg A, Siegfried E, et al. Laboratory safety of dupilumab in patients aged 6\u201311\u00a0years with severe atopic dermatitis: results from a phase\u00a0III clinical trial. Paediatr Drugs. 2021;23(5):515\u201327. https:\/\/doi.org\/10.1007\/s40272-021-00459-x.","journal-title":"Paediatr Drugs"},{"issue":"2","key":"3458_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40257-020-00583-3","volume":"22","author":"EC Siegfried","year":"2021","unstructured":"Siegfried EC, Bieber T, Simpson EL, et al. Effect of dupilumab on laboratory parameters in adolescents with atopic dermatitis: results from a randomized, placebo-controlled, phase\u00a03 clinical trial. Am J Clin Dermatol. 2021;22(2):243\u201355. https:\/\/doi.org\/10.1007\/s40257-020-00583-3.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"3458_CR25","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase\u00a0III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182(5):1120\u201335. https:\/\/doi.org\/10.1111\/bjd.18434.","journal-title":"Br J Dermatol"},{"key":"3458_CR26","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 5.0. 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 15 Jul 2025."},{"key":"3458_CR27","unstructured":"Nordic MPN Study Group. Guidelines for the diagnosis and treatment of eosinophilia. 3rd version. May 2018. https:\/\/nmpn.org\/index.php\/guidelines\/18-care-program-for-the-diagnosis-and-treatment-of-eosinophilia-3rd-version-may-2018\/file. Accessed 15 Jul 2025."},{"issue":"8","key":"3458_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1346-8138.1990.tb01679.x.","volume":"17","author":"H Mukai","year":"1990","unstructured":"Mukai H, Noguchi T, Kamimura K, et al. Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis. J Dermatol. 1990;17(8):477\u201381. https:\/\/doi.org\/10.1111\/j.1346-8138.1990.tb01679.x.","journal-title":"J Dermatol"},{"issue":"6","key":"3458_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1398-9995.2004.00476.x","volume":"59","author":"D Simon","year":"2004","unstructured":"Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy. 2004;59(6):561\u201370. https:\/\/doi.org\/10.1111\/j.1398-9995.2004.00476.x.","journal-title":"Allergy"},{"issue":"10","key":"3458_CR30","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695\u2013709. https:\/\/doi.org\/10.1016\/j.jaip.2022.05.019.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"3458_CR31","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174-90.e1. https:\/\/doi.org\/10.1016\/j.jaci.2021.01.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3458_CR32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaad.2024.03.027","volume":"91","author":"D Manzar","year":"2024","unstructured":"Manzar D, Suntres E, Nair N, Patel Y, Abu-Hilal M. Elevation of creatine phosphokinase in moderate-to-severe atopic dermatitis is associated with the use of JAK inhibitors but not dupilumab: a systematic review and meta-analysis. J Am Acad Dermatol. 2024;91(1):168\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.027.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3458_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","volume":"120","author":"M Boguniewicz","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10\u201322. E2. https:\/\/doi.org\/10.1016\/j.anai.2017.10.039.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3458_CR34","unstructured":"European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 2022. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic. Accessed 15 Jul 2025."},{"issue":"1","key":"3458_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/hematology.2020000116","volume":"2020","author":"L Malpica","year":"2020","unstructured":"Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematol Am Soc Hematol Educ Program. 2020;2020(1):319\u201327. https:\/\/doi.org\/10.1182\/hematology.2020000116.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"3458_CR36","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1016\/j.jaad.2022.12.029","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):E1\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.029.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3458_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/bjd\/ljae342","volume":"192","author":"C Haag","year":"2024","unstructured":"Haag C, Alexis A, Aoki V, et al. A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council. Br J Dermatol. 2024;192(1):135\u201343. https:\/\/doi.org\/10.1093\/bjd\/ljae342.","journal-title":"Br J Dermatol"},{"issue":"9","key":"3458_CR38","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s13555-024-01243-8","volume":"14","author":"MG Kirchhof","year":"2024","unstructured":"Kirchhof MG, Prajapati VH, Gooderham M, et al. Practical recommendations on laboratory monitoring in patients with atopic dermatitis on oral JAK inhibitors. Dermatol Ther (Heidelb). 2024;14(9):2653\u201368. https:\/\/doi.org\/10.1007\/s13555-024-01243-8.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03458-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03458-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03458-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:30:37Z","timestamp":1773822637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03458-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3458"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03458-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eric L. Simpson is a principal investigator or has received grants from AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Target, and Veriskin; and has received personal fess from AbbVie, Amgen, Arcutis, Astria Therapeutics, Castle, CorEvitas, Dermira, Eli Lilly, FIDE, Impetus Healthcare, Incyte, Innovaderm Recherches\/Indero, Janssen, LEO Pharma, Numab Therapeutics AG, Pfizer, Recludix Pharma, Regeneron Pharmaceuticals Inc., Roche Products Ltd, Sanofi, and Sitryx Therapeutics. Robert Bissonnette is a consultant and has received grants\/research support from AbbVie, Aclaris Therapeutics, Alumis, Amgen, Apogee Therapeutics, Arcutis Biotherapeutics, Areteia Therapeutics, Asana BioSciences, Attovia, BELLUS Health, BioMimetix, Bluefin Biomedicine, Boehringer Ingelheim, Boston Pharmaceuticals, Cara Therapeutics, Dermavant, Eli Lilly, Escient Pharmaceuticals, Evidera, Fresh Tracks Therapeutics (formerly Brickell Biotech), Galderma, GSK, Incyte, Inmagene Biopharmaceuticals, Janssen, LEO Pharma, Merck, Novartis, OPSIDIO, Pfizer, RAPT Therapeutics, Sanofi, Sitryx Therapeutics, Target RWE, VYNE Therapeutics, and Zencor; and is a shareholder of Innovaderm Research. Mette Deleuran has received research support\/consulting fees\/advisory board agreements, travel support, and\/or honoraria for lectures from AbbVie, Almirall, Eli Lilly, Incyte, Kymab, La Roche-Posay, LEO Pharma, Mustela, Numab, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., and Sanofi, and Union Therapeutics. Takeshi Nakahara has received laboratory funds from Maruho; and speaker fees from Maruho and Sanofi. Ryszard Galus is an investigator for and has received consulting fees from Amgen, Boehringer Ingelheim, Chugai, Dermira, Evelo Biosciences, Galderma, Glenmark, Incyte, Janssen, Kymab, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and UCB. Marjolein de Bruin-Weller is a consultant, advisory board member, and\/or speaker for AbbVie, Almirall, Eli Lilly, Galderma, Janssen, LEO Pharma, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and UCB. Michael van Spall and Mike Bastian are employees of Sanofi and may hold stock and\/or stock options in the company. Anna Coleman, Zhen Chen, Elena Avetisova, and Faisal A. Khokhar are employees and shareholders of Regeneron Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted following ethical principles derived from the Declaration of Helsinki, the International Conference for Harmonisation guideline, Good Clinical Practice guidelines, and applicable local regulatory requirements. The protocol was reviewed and approved by institutional review boards\/ethics committees at all centers. Written informed consent was obtained from all patients prior to commencement of any study procedures. A list of study investigators and a list of institutional review boards\/ethics committees are available in the supplemental materials (Table\u00a0\n                      \n                      and Table\u00a0\n                      \n                      , respectively).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}